1 / 15

Lung Transplantation

Lung Transplantation. Guidelines For Selection. Milpark Hospital Transplant Unit Johannesburg, South Africa. SATS Controversies Meeting May 2011. South African Guidelines based on : ATS - International Guidelines for the selection of Lung Transplant Candidates – 1998 ISHLT – Update – 2006

stavros
Download Presentation

Lung Transplantation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Lung Transplantation Guidelines For Selection Milpark Hospital Transplant Unit Johannesburg, South Africa SATS Controversies Meeting May 2011

  2. South African Guidelines based on: • ATS - International Guidelines for the selection of Lung Transplant Candidates – 1998 • ISHLT – Update – 2006 • GENERAL - Patient should be receiving or have received maximal medical therapy, but nevertheless have declining function, with a limited life expectancy ( <50% - 2-3 year survival). - The patient should have ambulatory and rehabilitation potential. - A satisfactory psycho-social profile with support systems is essential. AGE - Older patients have a significantly worse prognosis. - HLT <55 years. - BSLT <60 years. - SLT <65 years. BMI - 18 – 30%

  3. Lung Transplantation as the sole form of therapy is potentially indicated in any irreversible condition, resulting in either one or both of the following disease entities: • END STAGE RESPIRATORY FAILURE. (ICD 10 CODE: J96.1) • PULMONARY ARTERIAL HYPERTENSION. (ICD 10 CODE: I27.0) (ICD 10 CODE: Q20 – 28) Refer for Assessment at this Stage and Exclude Unsuitable Recipients following Review of Disease Specific Guidelines

  4. A. End Stage Respiratory Failure Conditions grouped as follows: •COPD (ICD 10 Code: J40 -J46) - Acquired. - Congenital (Alpha1 – Antitrypsin def.). • Idiopathic Pulmonary Fibrosis (IPF). (ICD 10 Code: J80-J84) • Infective/Inflammatory. (ICD 10 Code: J47 .xx, J60-J70,J85-J86 E84 & other) - Cystic Fibrosis (CF). - Bronchiectasis. - Sarcoidosis. - Other e.g. – LAM etc. B. Pulmonary Hypertension - Primary (PPH). - Secondary.

  5. Disease Specific Criteria COPD • FEV¹ <25% of predicted. • PaCO² > 55/PHT. • Progressive deterioration on Domiciliary Oxygen. • Frequent admissions with declining function. • Patients with a high BODE index. • Patients not better served by LVRS.

  6. Disease Specific Criteria – cont. IPF • Symptomatic disease. • Exercise desaturation. • VC < 60 – 75% predicted. • DLCO < 50 – 60% predicted.

  7. Disease Specific Criteria – cont. Infective/Inflammatory (CF) • FEV¹ < 30% predicted. • High Risk Patients: - Young Females with a rapidly declining FEV¹. - Weight Loss. - Frequent Infective Exacerbations. - Haemoptysis.

  8. Disease Specific Criteria – cont. PPH • NYHA Class III/IV on optimal treatment – Epoprostanol/Sildenafil/Bosentan. • Declining Functional Capacity.

  9. Disease Specific Criteria – cont. EISENMENGERS SYNDROME (2° PAT) •NYHA Class III/IV and Declining Functional Capacity.

  10. Contra-indications • HIV+ve/AIDS. • Hepatitis B, Ag+ve. • Hepatitis C with biopsy proven liver disease. • Active malignancy. • Dysfunction of one or more major organ. systems other than lungs, e.g. renal failure.

  11. Relative Contra-indications In combination – increases risk of Tx • Severe Osteoporosis. • Hypertension. • Diabetes Mellitus. • Peptic Ulcer Disease. • Musculo-skeletal Disease eg. Kypho-scoliosis • Long term, high dose corticosteroids. • Poor nutritional status. • Substance abuse. • Psychological disorders. • Mechanical ventilation. • Microbial colonisation. • T.B. (untreated).

  12. Conclusions • Most patients with diagnosis of IPF/UIP SHOULD be considered for EARLY transplant listing – due to rapid progression of disease. • Very FEW patients with COPD/Airway obstruction WOULD be considered suitable for listing – advanced age with co-morbid disease.

  13. Conclusions •Worldwide the percentage of patients undergoing transplantation with PAH is DIMINISHING due to improved prognosis with medical therapy. • A large and increasing percentage of CYSTIC FIBROSIS patients could potentially qualify for listing, although some patients currently elect not to follow this route.

  14. Conclusions • Meeting disease specific criteria generally implies transplant ASSESSMENT is indicated. Certain percentage will be excluded by Transplant Panel. • It is in the interest of the Transplant Team to rigorously accept only ideal recipient.

More Related